Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05345171 · ClinicalTrials.gov registry record · Phase 3
Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
A Phase 3 study of OTC Deficiency, sponsored by Ultragenyx Pharmaceutical.
- Active
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 16
- Study locations
NCT05345171 is a Phase 3 study of OTC Deficiency that is active but no longer recruiting, run by Ultragenyx Pharmaceutical. The registered enrollment target is 32 participants. The trial reports 16 study locations across 6 states.
The verdict
NCT05345171, a Phase 3 study of OTC Deficiency, is active but no longer recruiting, sponsored by Ultragenyx Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels.
Conditions Studied
Interventions
- OTHER Placebo
- GENETIC DTX301
- DRUG Oral Corticosteroids
- DRUG Placebo for oral corticosteroids
- DRUG Sodium Acetate
Study Locations (16)
Other
- Hospital Italiano de Buenos Aires - Buenos Aires
- Clinica Universitaria Reina Fabiola - Córdoba
- Hospital de Clinicas de Porto Alegre - Porto Alegre
- Hopital Femme Mere Enfant - Bron
- Necker-Enfants Maladas Hospital - Paris
- Universitatsklinikum Heidelberg - Heidelberg
- Kumamoto University Hospital - Kumamoto
- Fujita Health University Hospital - Toyoake
- Erasmus Universitair Medisch Centrum Rotterrdam - Rotterdam
- Centro Hospitalar Universitario de Sao Joao - Porto
- Fundacio Hospital Universitari Vall D'Hebron-Institute de Recerca - Barcelona
California
- University of California - Los Angeles
Colorado
- University of Colorado - Aurora
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Ontario
- The Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2031-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05345171
The ClinicalTrials.gov registry entry for NCT05345171 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with OTC Deficiency appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT05345171 reports 16 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05345171 about?
NCT05345171 is a clinical study titled "Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency". The primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels.
What is the current status of trial NCT05345171?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2022-10-18. Estimated completion is 2031-03.
What conditions does trial NCT05345171 study?
This clinical trial studies the following conditions: OTC Deficiency.
What interventions are being tested in trial NCT05345171?
The interventions under investigation include: Placebo (OTHER), DTX301 (GENETIC), Oral Corticosteroids (DRUG), Placebo for oral corticosteroids (DRUG), Sodium Acetate (DRUG).
Who is sponsoring clinical trial NCT05345171?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05345171 being conducted?
This trial has 16 study locations across California, Colorado, Illinois, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OTC Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.